Abstract Details

Title A randomized, placebo-controlled, double-blind, Phase 1b/2 study of the novel anti-myostatin adnectin RG6206 (BMS-986089) in ambulatory boys with Duchenne muscular dystrophy

Topic Neuromuscular and Clinical Neurophysiology (EMG)

Presentation(s) P5 - (-)

Poster/Presentation
Number 431

Background

Objective

Design/Methods

Results

Conclusions

Authors/Disclosures
Kathryn R. Wagner, MD, PhD (The Kennedy Krieger Institute) PRESENTER	Dr. Wagner has received personal compensation for serving as an employee of F. Hoffmann-La Roche Ltd. Dr. Wagner has stock in F. Hoffmann-La Roche.
Brenda L. Wong, MD (University of Massachusetts Medical School)	No disclosure on file
Barry Byrne	No disclosure on file
	No disclosure on file
	No disclosure on file
Joshua Tam, MD, PhD (Princess Alexandra Hospital)	No disclosure on file
Michael Rabbia	No disclosure on file
Jeppe Buchbjerg, PhD	No disclosure on file
	No disclosure on file
Clifford Bechtold	No disclosure on file